These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2150826)
1. [Long-term effects of indobufen on several parameters of blood platelet function in subjects at thrombotic risk]. Di Blasi S; Pintacuda S; Ferotti N; Lo Coco L; Muratore A; Russo G; Di Blasi U; D'Alessandro M; Morici G; Fornaciari M G Clin Med; 1990 Dec; 71(12):727-31. PubMed ID: 2150826 [TBL] [Abstract][Full Text] [Related]
2. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients. Dmoszyńska A; Janicki K; Janicka L; Przesmycki K; Sokołowska B; Walter-Croneck A Pol J Pharmacol; 1996; 48(3):327-9. PubMed ID: 9112671 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of morning platelet aggregation in patients with ischemic cardiopathy after evening administration of indobufen]. Craveri A; Lanfredini M; Citella C; Braconaro F; Colombo L Minerva Cardioangiol; 1988 Sep; 36(9):411-8. PubMed ID: 3226570 [No Abstract] [Full Text] [Related]
5. [Activation and functions of blood platelets in patients with diabetes mellitus type 1 before and during the treatment with indobufen]. Dmoszyńska-Giannopoulou A; Sokołowska B; Ledwozyw A Pol Arch Med Wewn; 1990 Mar; 83(3):97-103. PubMed ID: 2216938 [TBL] [Abstract][Full Text] [Related]
6. A prostacyclin-sparing effect of indobufen vs. aspirin. De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417 [TBL] [Abstract][Full Text] [Related]
7. Comparison of aspirin and indobufen in healthy volunteers. Lee JY; Sung KC; Choi HI Platelets; 2016; 27(2):105-9. PubMed ID: 26083594 [TBL] [Abstract][Full Text] [Related]
8. Indobufen induced modification of phospholipid composition in diabetic platelets. Dmoszyńska A; Sokołowska B; Walter-Croneck A; Przesmycki K; Ledwozyw A Pol J Pharmacol; 1996; 48(3):331-4. PubMed ID: 9112672 [TBL] [Abstract][Full Text] [Related]
9. Effects of short-term treatment with the thromboxane synthesis blocker indobufen on pressor and depressor humoral factors in healthy humans. Zacharieva S; Orbetzova M; Tcharaktchiev D; Angelova-Gateva P; Andonova K Methods Find Exp Clin Pharmacol; 1995 Nov; 17(9):615-9. PubMed ID: 8786676 [TBL] [Abstract][Full Text] [Related]
10. [The effect of indobufen on platelet function and dialyzer regeneration in patients on hemodialysis]. Sokołowska B; Dmoszyńska A; Janicka L; Walter-Croneck A Pol Arch Med Wewn; 1995 Jun; 93(6):475-82. PubMed ID: 7491347 [TBL] [Abstract][Full Text] [Related]
11. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen. Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004 [TBL] [Abstract][Full Text] [Related]
12. [Clinical-experimental studies on the inhibition of thrombocyte function with acetylsalicylic acid and with indobufen]. Vinazzer H Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):783-96. PubMed ID: 94870 [TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen. Mamiya S; Hagiwara M; Ishikawa T; Hidaka H Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401 [TBL] [Abstract][Full Text] [Related]
14. Preliminary studies on indobufen (K 3920). A new inhibitor of platelet aggregation. Gürsoy AZ; Yardimci TU; Emekli NB; Ugur MS; Ulutin ON Haematologica; 1981 Dec; 66(6):756-67. PubMed ID: 6802717 [No Abstract] [Full Text] [Related]
15. Beta-thromboglobulin and platelet factor 4 plasma levels during haemodialysis: effect of indobufen. Pogliani EM; Colombi M; Cristoforetti G; Valenti G; Miradoli R; Buccianti G Pharmatherapeutica; 1982; 3(2):127-32. PubMed ID: 6179101 [TBL] [Abstract][Full Text] [Related]
16. [Clinical contribution to the study of indobufen, a new platelet aggregation inhibitor]. Ciammaichella A; Luzi M; Pezzi F; Recchia O Clin Ter; 1982 Aug; 102(4):387-95. PubMed ID: 6754219 [No Abstract] [Full Text] [Related]
17. Long-term trial (6 months) of the platelet aggregation inhibitory activity and biological safety of indobufen in cerebrovascular patients. Mansi D; Majello L; Palma V; De Michele G; Buscaino GA Acta Neurol (Napoli); 1983 Dec; 5(6):447-55. PubMed ID: 6367383 [No Abstract] [Full Text] [Related]
18. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Mannucci L; Maderna P; Colli S; Lavezzari M; Sirtori CR; Tremoli E Thromb Res; 1987 Nov; 48(4):417-26. PubMed ID: 3445229 [TBL] [Abstract][Full Text] [Related]
19. [Effect of indobufen on leukocyte-dependent thrombocyte aggregation in patients with ischemic heart disease]. Liusov VA; Diukov IV; Uteshev DV Kardiologiia; 1993; 33(4):22-3. PubMed ID: 7933785 [No Abstract] [Full Text] [Related]
20. A comparative study between indobufen and acetylsalicylic acid on beta-thromboglobulin, platelet factor 4 and platelet aggregation in patients with transient ischemic attacks. Orefice G; Carrieri P; Indaco A; Iorillo L; Fioretti A Acta Neurol (Napoli); 1984 Apr; 6(2):97-103. PubMed ID: 6204513 [No Abstract] [Full Text] [Related] [Next] [New Search]